Royston Aaron's Form 4 filing
Achieve Life Sciences, Inc. (ACHV) · filed Jul 29, 2026
- Accession no.
- 0001193125-26-324253
- Filed
- Jul 29, 2026, 5:22 PM ET
- Trade date
- Jul 27, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Royston AaronCIK 0001727703 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Common Stock | AGrant or awardAcquired | +25,000 | $0.00 | $0 | 25,000 | Direct | |
| Jul 27, 2026 | Common Stock | AGrant or awardAcquired | +16,700 | $0.00 | $0 | 16,700 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Dr. Royston is a member of venBio Global Strategic GP V, LLC, which is the general partner of venBio Global Strategic Fund V, L.P. ("venBio V"), and is a member of the board of directors of the Issuer. These options and RSUs are held by Dr. Royston for the benefit of venBio V. Pursuant to policies of venBio Partners, the manager of venBio V, with respect to director compensation, upon the exercise of these options, the vesting and settlement of these RSUs, and the sale of the underlying securities, the proceeds will be remitted to venBio V. Dr. Royston disclaims beneficial ownership over the shares underlying the options and RSUs held for the benefit of venBio V except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or any other purpose.